Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania. As of January 28, 2020, Achillion Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Company Website : http://www.achillion.com
Address : 300 George Street 06511,New Haven,USA
Employees : 56
Fiscal Year End : December
Currency: USD
Country : USA
Beta : 1.59
Shorted Shares : 8,603,331
200 Day Moving Average : 5.74
Shorted Shares Previous Month : 8,832,343
50 Day Moving Average : 6.76
| Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
|---|---|---|---|---|---|
| LGCY | Legacy Reserves Inc |
N/A |
USD61,525,874.67B | 1.10 | 5.30 |
| FTD | FTD Companies, Inc |
N/A |
USD28,725,913.80B | N/A | N/A |
| KEYW | The KeyW Holding Corporation |
N/A |
USD24,651,104.38B | 166.80 | 24.48 |
| SNHY | Helios Technologies, Inc |
N/A |
USD17,848,852.22B | 1,000,000.00 | N/A |
| QTNA | Quantenna Communications, Inc |
N/A |
USD8,997,243.52B | 175.07 | 79.98 |
| INSY | INSYS Therapeutics, Inc |
N/A |
USD4,995,459.82B | 115.90 | N/A |
| CHKE | Apex Global Brands Inc |
N/A |
USD384,202.91B | 17.30 | N/A |
| AMCN | AirNet Technology Inc |
N/A |
USD308,457.30B | 1.00 | N/A |
| PDVW | pdvWireless, Inc |
N/A |
USD95,944.74B | N/A | N/A |
| AIPT | Predictive Oncology Inc |
N/A |
USD38,513.36B | N/A | N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|
| Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 12 Months | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Trailing 5 Years | |||||||
| Capital Gain | 1,473.68% | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1,473.68% | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 581.87% | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 581.87% | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 1,075.20% | N/A | N/A | N/A | N/A | ||
| Risk Adjusted Return | 54.12% | N/A | N/A | N/A | N/A | ||
| Market Capitalization | 0.95B | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| Market Value | |||||||
| Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Price/Book Ratio | 4.36 | N/A | N/A | N/A | N/A | ||
| Price / Cash Flow Ratio | -15.27 | N/A | N/A | N/A | N/A | ||
| EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
| Management Effectiveness | |||||||
| Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
| Return on Invested Capital | -25.05% | N/A | N/A | N/A | N/A | ||
| Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
| Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Technical Ratios | |||||||
| Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
| Short Percent | N/A | N/A | N/A | N/A | N/A | ||
| Beta | 1.59 | N/A | N/A | N/A | N/A | ||
| Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
| A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
| B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
| C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
| D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
| F | 0%-59% |
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
No discussions yet
| User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
The company had negative total cash flow in the most recent four quarters.
Do not have an account? Register here
